Table 1.
Background characteristics for total cases (n = 220) and repeated cases (n = 53).
| Characteristic | Total (n = 220) | Repeated (n = 53) |
|---|---|---|
| Age, range, y | 76 (38–95) | 76 (54–89) |
| Sex (male/female), n | 143/77 | 40/13 |
| Etiology (HBV/HCV/NBNC), n | 32/143/48 | 7/39/7 |
| Child–Pugh score (5/6/7), n | 148/49/23 | 41/9/3 |
| Platelet count, range, ×104/μL | 11.5 (2.8–33.2) | 10.8 (4.6–32.7) |
| Albumin, range, g/dL | 3.9 (2.7–5.1) | 4.1 (3.0–5.0) |
| Total bilirubin, range, mg/dL | 0.8 (0.2–2.8) | 0.8 (0.4–2.0) |
| Prothrombin activity, range, % | 85 (32–119) | 87 (43–119) |
| ALBI score, range | −2.60 (−3.70–1.31) | −2.76 (−3.70–1.80) |
| Size of main tumor, range, mm | 16 (8–50) | 17 (8–35) |
| Number of tumors (1/2), n | 201/19 | 50/3 |
| Treatment-naïve before first SBRT/Recurrence, n | 48/172 | 6/47 |
| Serum AFP value, range, ng/mL | 6.5 (0.5–4470) | 8 (1.6–313.5) |
| Serum DCP value, range, mAU/mL | 26 (1.9–3811) | 24.5 (10–592) |
| BCLC stage (0/A), n | 101/119 | 24/29 |
| Previous TACE before SBRT (with/without), n | 191/29 | 46/7 |
| Dose/fractions (prescription) | ||
| 40 Gy/4–5 fractions, n | 112 | 27 |
| 48 Gy/4 fractions, n | 86 | 21 |
| 60 Gy/8 fractions, n | 22 | 5 |
Values represent median (range) or number of patients. HBV—hepatitis B virus infection; HCV—hepatitis C virus infection; NBNC—non-B, non-C viral hepatitis; ALBI—albumin-bilirubin; AFP—alpha-fetoprotein; DCP—des-γ-carboxy prothrombin; BCLC—Barcelona Clinic Liver Cancer; TACE—transarterial chemoembolization; SBRT—stereotactic body radiation therapy.